NZ237784A - Monoclonal antibody binding to igm but not igg 1 or igg 2 having a g isotype; hybridomas and immunotoxins - Google Patents

Monoclonal antibody binding to igm but not igg 1 or igg 2 having a g isotype; hybridomas and immunotoxins

Info

Publication number
NZ237784A
NZ237784A NZ237784A NZ23778491A NZ237784A NZ 237784 A NZ237784 A NZ 237784A NZ 237784 A NZ237784 A NZ 237784A NZ 23778491 A NZ23778491 A NZ 23778491A NZ 237784 A NZ237784 A NZ 237784A
Authority
NZ
New Zealand
Prior art keywords
antibody
igm
monoclonal antibody
conjugate
cells
Prior art date
Application number
NZ237784A
Other languages
English (en)
Inventor
Michael G Rosenblum
Nicholas J Donato
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of NZ237784A publication Critical patent/NZ237784A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ237784A 1990-04-27 1991-04-10 Monoclonal antibody binding to igm but not igg 1 or igg 2 having a g isotype; hybridomas and immunotoxins NZ237784A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51597490A 1990-04-27 1990-04-27

Publications (1)

Publication Number Publication Date
NZ237784A true NZ237784A (en) 1992-09-25

Family

ID=24053580

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ237784A NZ237784A (en) 1990-04-27 1991-04-10 Monoclonal antibody binding to igm but not igg 1 or igg 2 having a g isotype; hybridomas and immunotoxins

Country Status (12)

Country Link
EP (1) EP0538267A4 (ru)
JP (1) JPH06504424A (ru)
CN (1) CN1057072A (ru)
CA (1) CA2079901A1 (ru)
IE (1) IE911172A1 (ru)
IL (1) IL97827A0 (ru)
NZ (1) NZ237784A (ru)
PT (1) PT97482B (ru)
RU (1) RU2105062C1 (ru)
TW (1) TW349995B (ru)
WO (1) WO1991017257A1 (ru)
ZA (1) ZA912695B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322562B1 (en) 2008-09-05 2016-03-30 Sekisui Medical Co., Ltd. Monoclonal antibody, and immunoassay using same
CN108384761B (zh) * 2018-03-30 2020-08-11 四川迈克生物新材料技术有限公司 抗人IgM单克隆抗体、其杂交瘤细胞株及应用
WO2023088443A1 (zh) * 2021-11-20 2023-05-25 东莞市朋志生物科技有限公司 一种抗人IgM抗体及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792447A (en) * 1981-07-23 1988-12-20 Board Of Regents, The University Of Texas System Anti-immunoglobulin toxin conjugates useful in the treatment of B cell tumors
WO1992007574A1 (en) * 1990-10-25 1992-05-14 Tanox Biosystems, Inc. Glycoproteins associated with membrane-bound immunoglobulins as antibody targets on b cells

Also Published As

Publication number Publication date
CA2079901A1 (en) 1991-10-28
TW349995B (en) 1999-01-11
EP0538267A1 (en) 1993-04-28
ZA912695B (en) 1993-02-24
PT97482A (pt) 1992-01-31
PT97482B (pt) 1998-08-31
IE911172A1 (en) 1991-11-06
AU7866491A (en) 1991-11-27
IL97827A0 (en) 1992-06-21
AU650659B2 (en) 1994-06-30
CN1057072A (zh) 1991-12-18
RU2105062C1 (ru) 1998-02-20
WO1991017257A1 (en) 1991-11-14
JPH06504424A (ja) 1994-05-26
EP0538267A4 (en) 1994-06-01

Similar Documents

Publication Publication Date Title
EP0153114B1 (en) Monoclonal anti-human breast cancer antibodies, their production and use, and hybridomas for producing the same and their preparation
US5169774A (en) Monoclonal anti-human breast cancer antibodies
EP0068763B2 (en) Recombinant monoclonal antibodies
Mason et al. Preparation of peroxidase: antiperoxidase (PAP) complexes for immunohistological labeling of monoclonal antibodies.
EP0450479A1 (en) Bispecific monoclonal anti-bodies, their production and use
US20020025319A1 (en) Antibodies that bind phosphatidyl serine and a method of their use
NO174719B (no) Fremgangsmaate for fremstilling av monoklonale antistoffer
AU599364B2 (en) Methods and compositions for the identification of metastatic human tumors
US6306626B1 (en) Anti-IgM monoclonal antibodies and methods of their use
CA1297048C (en) Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
US5158886A (en) Monoclonal antibodies specific for free N-acetylfuraminic acid and beta-glycosides and beta-glycoconjugates thereof
NZ237784A (en) Monoclonal antibody binding to igm but not igg 1 or igg 2 having a g isotype; hybridomas and immunotoxins
US5053492A (en) Immunopurification using monoclonal antibodies to Mojave toxin
AU650659C (en) Monoclonal anti-IgM antibodies, their production and use, and hybridomas for producing the same
Niemann et al. The use of monoclonal antibodies as probes of the three-dimensional structure of human complement factor D.
METTLER et al. Monoclonal sperm antibodies: their potential for investigation of sperms as target of immunological contraception
NO174005B (no) Monoklonalt antistoff, hybridom, og reagens for immunologisk analyse av alfa-hanp
CA1253090A (en) Monoclonal anti-human breast cancer antibodies
Bashir et al. Generation of a monoclonal antibody to P-glycoprotein peptides using tuberculin-PPD as a carrier
JPH05168494A (ja) ハイブリッド・モノクローナル抗体および抗体含有薬剤
WO1994016735A1 (en) Anti-zona pellucida antibodies for delivery of therapeutic agents to the ovary
HUMAN FACTOR D1
Safi et al. Two antigens detected on human ocular melanomas with the mouse monoclonal antibodies 2/10SN and 10/12SN
EP0439117A1 (en) Monoclonal antibodies which bind (E)-5-(2-bromovinyl)-arabinofuranosyluracil and diagnostic methods based thereon
CA2056118A1 (en) Monoclonal antibodies which bind mannose binding protein